Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Gamma-aminobutyric acid receptor-associated protein-like 2 (GABARAPL2) is a ubiquitin-like modifier and autophagy-related protein belonging to the ATG8 family, encoded by the GABARAPL2 gene in humans[2][4][5]. GABARAPL2 is involved in several critical cellular processes, most notably the maturation of autophagosomes (a structure important for cellular autophagy), intra-Golgi traffic, and regulation of mitophagy[2]. GABARAPL2 binds to phosphatidylethanolamine and ubiquitin protein ligases and interacts with proteins such as ULK1, ATG4B, FAM134B, and UBA5 via LC3-interacting regions (LIRs)[2][3][4]. Its biological roles center on protein trafficking, autophagosome maturation, and negative regulation of proteasomal protein degradation. GABARAPL2 has disease links to conditions involving dysfunctional autophagy, including certain neurodegenerative diseases and cancers, though direct drug targeting or biomarker use is not established as of current knowledge[2][4]. Note: GABARAPL2 does not directly bind GABA type A receptors (despite its name)—that function is attributed to the related proteins GABARAP and GABARAPL1[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Gamma-aminobutyric acid receptor-associated protein-like 2 (GABARAPL2).